ArticleFrontiers in oncology2023

Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma.

Chien-Yu Tseng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.